GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
Key Takeaways GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs.
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and reported strong financial results for 2024. The stock climbed 5.9% in early trading,
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted fourth-quarter profit ahead of analyst expectations.
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on Wednesday.
GSK raises long-term guidance, announces buybacks
GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025. The company disclosed £8.
GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
pharmaphorum9d
GSK hunts for new CEO as Novartis asset swap starts to pay off
GlaxoSmithKline (GSK) appears to be focusing more on finding a new CEO than any large M&A deals after last year's $20 billion asset swap with Novartis, according to a briefing following strong ...
Bloomberg L.P.23d
GSK CEO Optimistic About Dealmaking, Trump Administration
GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in ...
MM&M6d
Takeda CEO Christophe Weber to retire in 2026, Julie Kim to succeed him
Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.
Yahoo Finance23d
GSK CEO on US Expansion, M&A, Drug Pipeline, Trump
GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio in the US, their overall drug pipeline and working with Robert F.
FiercePharma22d
JPM25: GSK, Sanofi CEOs welcome 'transparency' in response to anti-vaccine movement in US
Kennedy Jr. to run the Department of Health and Human Services. How do Sanofi CEO Paul Hudson and GSK CEO Emma Walmsley—who lead two of the top vaccine companies in the world—feel about the ...